Foghorn Therapeutics (FHTX)
(Delayed Data from NSDQ)
$6.25 USD
-0.36 (-5.45%)
Updated Jul 24, 2024 04:00 PM ET
After-Market: $6.33 +0.08 (1.28%) 7:58 PM ET
3-Hold of 5 3
F Value F Growth D Momentum F VGM
Brokerage Reports
Foghorn Therapeutics Inc. [FHTX]
Reports for Purchase
Showing records 1 - 20 ( 79 total )
Company: Foghorn Therapeutics Inc.
Industry: Medical - Drugs
Where the Brook Is Deep; State of Acute Myeloid Leukemia Treatment
Provider: Wedbush Securities Inc.
Analyst: DRISCOLL R
Company: Foghorn Therapeutics Inc.
Industry: Medical - Drugs
Near/Long-Term Value Driven by FHD-286 in AML (2H24) And Diverse Pipeline Optionality
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Company: Foghorn Therapeutics Inc.
Industry: Medical - Drugs
Company: Foghorn Therapeutics Inc.
Industry: Medical - Drugs
Why Investors Should Take Note of the Renaissance Happening in Chromatin Biology
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Company: Foghorn Therapeutics Inc.
Industry: Medical - Drugs
Company: Foghorn Therapeutics Inc.
Industry: Medical - Drugs
AACR?24 Event Highlights Formidable Novel Oncology Agents; Reit. Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Company: Foghorn Therapeutics Inc.
Industry: Medical - Drugs
Showcases Robust Pipeline, Capabilities; Shares Appear Attractive
Provider: Wedbush Securities Inc.
Analyst: DRISCOLL R
Company: Foghorn Therapeutics Inc.
Industry: Medical - Drugs
Cutting Through the Fog of Drug Development With Multiple Attacks on BAF: Reit Buy and $20
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Company: Foghorn Therapeutics Inc.
Industry: Medical - Drugs
Company: Foghorn Therapeutics Inc.
Industry: Medical - Drugs
Q4 Financials; CBP/EP300 Data at AACR, FHD-286 Data in 2H:24
Provider: Wedbush Securities Inc.
Analyst: DRISCOLL R
Company: Foghorn Therapeutics Inc.
Industry: Medical - Drugs
Q4 Financials; CBP/EP300 Data at AACR, FHD-286 Data in 2H:24
Provider: Wedbush Securities Inc.
Analyst: DRISCOLL R
Company: Foghorn Therapeutics Inc.
Industry: Medical - Drugs
Lily?s Selection of Foghorn?s FHD-909 Reinforces the Druggability of the Chromatin Remodeling System (CRS); Reit. Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Company: Foghorn Therapeutics Inc.
Industry: Medical - Drugs
Company: Foghorn Therapeutics Inc.
Industry: Medical - Drugs
Company: Foghorn Therapeutics Inc.
Industry: Medical - Drugs
Company: Foghorn Therapeutics Inc.
Industry: Medical - Drugs
Company: Foghorn Therapeutics Inc.
Industry: Medical - Drugs
A Powerhouse of CRS Targeting Via Enzyme Inhibitors and Degraders: Reit. Buy and $20 PT
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Company: Foghorn Therapeutics Inc.
Industry: Medical - Drugs
FHD-286 AML Study Start in 3Q23, With Attractive Earlier-Stage Assets; Reit. Buy and $20 PT
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Company: Foghorn Therapeutics Inc.
Industry: Medical - Drugs
Company: Foghorn Therapeutics Inc.
Industry: Medical - Drugs
FHD-286 UM Update Refocuses Program Toward AML, Which We View As a Net Positive
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A